Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Odalasvir and AL-335 Regimens in HCV
NCT03099135Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of odalasvir, adafosbuvir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Started Apr 2017; status: terminated.
02
Drugs
odalasviradafosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03099135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099135.